Anticipatory discovery of entry inhibitors against emerging viruses guided by viral phylogeny
Preprint
Abstract
Emerging viruses pose a major threat to global health, underscoring the need to improve antiviral preparedness. Here, we developed a phylogenetically-informed framework to identify entry inhibitors with potential activity against yet-to-emerge viruses. First, using pseudotypes displaying the receptor-binding proteins (RBPs) of 8 enveloped RNA viruses from different families, we screened a library of 2,320 FDA-approved compounds to identify candidate entry inhibitors. Hits were tested for potency, selectivity, consistency across cell types and pseudotyping vectors and, in some cases, were validated using authentic viruses. Then, to define the breadth of antiviral activity, 25 selected drugs were assayed against an expanded panel of 68 RBPs from 13 families, as well as against pairs of closely related RBPs. This revealed both narrow and broad-range inhibitors, including selective estrogen receptor modulators, alkaloids, aminoquinolines, and anidulafungin, which showed particularly broad activity. Importantly, RBPs from the same phylogenetic cluster frequently displayed correlated drug-sensitivity profiles, indicating that antiviral effects are predictable across closely related viruses. Our findings provide a proof of concept for anticipatory antiviral discovery, showing that phylogenetic relationships can guide the identification of entry inhibitors against potential future zoonotic threats.Keywords
Funding Information
- Generalitat Valenciana (CIGRIS/2023/199)
- European Research Council (101019724—EVADER)
- Ministerio de Ciencia, Innovación y Universidades (PID2020-118602RB-I00-ZooVir)
- Ministerio de Ciencia, Innovación y Universidades (RYC2024-050335-I)
- European Commission (101104880)
This publication has 27 references indexed in Scilit:
- Drug repositioning as a promising approach for the eradication of emerging and re-emerging viral agentsMolecular Diversity, 2025
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and controlSignal Transduction and Targeted Therapy, 2024
- Pharmacological effect of cepharanthine on SARS-CoV-2–induced disease in a Syrian hamster modelJournal of Infection and Chemotherapy, 2024
- Pseudotyped Viruses2023
- Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entrySignal Transduction and Targeted Therapy, 2021
- High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2ACS Infectious Diseases, 2020
- High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle systemAntiviral Research, 2018
- Synergistic drug combination effectively blocks Ebola virus infectionAntiviral Research, 2017
- Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugsEmerging Microbes & Infections, 2014
- Quantitative PCR technique for detecting lymphocytic choriomeningitis virus in vivoJournal of Virological Methods, 2008